<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604278</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237A2316</org_study_id>
    <secondary_id>2011-005673-23</secondary_id>
    <nct_id>NCT01604278</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>GLOW6</acronym>
  <official_title>A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assessed the efficacy, safety and tolerability of the co-administration of NVA237
      plus indacaterol taken once daily versus indacaterol taken once daily in patients with
      moderate to severe Chronic Obstructive Pulmonary Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume at 1 Second (FEV1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at Individual Time-points</measure>
    <time_frame>Day 1, Day 29, Day 57 and Days 84/85</time_frame>
    <description>Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at Individual Time-points</measure>
    <time_frame>Day 1, Day 29, Day 57 and Days 84/85</time_frame>
    <description>FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC) at Individual Time-points</measure>
    <time_frame>Day 1, Days 84/85</time_frame>
    <description>Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Daily Number of Puffs of Rescue Medication</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transitional Dyspnea Index (TDI) Focal Score</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Daily Total and Individual Symptom Scores</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>NVA237 + indacaterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to NVA237 + indacaterol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 50 µg and indacaterol 150 µg</intervention_name>
    <description>NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.</description>
    <arm_group_label>NVA237 + indacaterol</arm_group_label>
    <other_name>Glycopyrronium Bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to NVA237 and indacaterol 150 µg</intervention_name>
    <description>Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.</description>
    <arm_group_label>Placebo to NVA237 + indacaterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage
             II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) Guidelines.

          -  Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30 %
             and/or &lt;80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital
             Capacity (FVC) &lt; 0.70 at screening.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years

          -  Symptomatic patients according to daily diary data.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential unless using adequate contraception.

          -  Patients with Type I or uncontrolled Type II diabetes.

          -  Patients with a history of long time interval between start of Q wave and end of T
             wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart
             rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged

          -  Patients with paroxysmal (e.g. intermittent) atrial fibrillation

          -  Patients who have a clinically significant electrocardiogram (ECG) or laboratory
             abnormality at screening (Visit 2)

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gosselies</city>
        <zip>6041</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herentals</city>
        <zip>2200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jambes</city>
        <zip>5100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmedy/Bellevaux-Ligneuville</city>
        <zip>4960</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montigny-le-tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>564 03</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1046</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erd</city>
        <zip>H-2030</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Godollo</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <state>Slovak Republic</state>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bojnice</city>
        <state>Slovak Republic</state>
        <zip>972 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <state>Slovak Republic</state>
        <zip>033 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Námestovo</city>
        <state>Slovensko</state>
        <zip>02901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>077 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gijon</city>
        <state>Asturias</state>
        <zip>33290</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrelavega</city>
        <state>Cantabria</state>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Illescas</city>
        <state>Castilla la Mancha</state>
        <zip>45200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponferrada</city>
        <state>Castilla y Leon</state>
        <zip>24400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Centelles</city>
        <state>Cataluña</state>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt</city>
        <state>Cataluña</state>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <state>Cataluña</state>
        <zip>08830</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viladecans</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mérida</city>
        <state>Extremadura</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34854</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mersin</city>
        <zip>33079</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yenisehir/Izmir</city>
        <zip>35110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burnhope</city>
        <state>County Durham</state>
        <zip>DH7 0BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alderton</city>
        <state>Suffolk</state>
        <zip>IP12 3DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atherstone</city>
        <state>Warwickshire</state>
        <zip>CV9 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leamington Spa</city>
        <state>Warwickshire</state>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strensall</city>
        <state>Yorkshire</state>
        <zip>YO32 5UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bath</city>
        <zip>BA1 2SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bexhill-on-Sea</city>
        <zip>TN40 1JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB7 5JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntingdon</city>
        <zip>PE29 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newton Aycliffe</city>
        <zip>DL5 4SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reading</city>
        <zip>RG7 3SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Telford</city>
        <zip>TF1 6TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Watford</city>
        <zip>WD25 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiltshire</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <results_first_submitted>July 28, 2014</results_first_submitted>
  <results_first_submitted_qc>November 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2014</results_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indacaterol</keyword>
  <keyword>Glycopyrronium Bromide</keyword>
  <keyword>COPD</keyword>
  <keyword>bronchodilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The number of patients randomized was 449. Of these participants, the Full Analysis Set (FAS) comprised 446 participants who received at least one dose of study drug and had no major deviations which led to removal from the FAS. The Safety Set included 447 participants who received at least one dose of study drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NVA237 + Indacaterol</title>
          <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
        </group>
        <group group_id="P2">
          <title>Placebo to NVA237 + Indacaterol</title>
          <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="221">Two randomized participants who did not receive study drug were excluded from this set.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="220">Three randomized participants excluded: 2 who did not receive study drug; 1 with a major deviation.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline characteristics table was based on the safety set.</population>
      <group_list>
        <group group_id="B1">
          <title>NVA237 + Indacaterol</title>
          <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
        </group>
        <group group_id="B2">
          <title>Placebo to NVA237 + Indacaterol</title>
          <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="221"/>
            <count group_id="B3" value="447"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="8.44"/>
                    <measurement group_id="B2" value="64.1" spread="7.67"/>
                    <measurement group_id="B3" value="63.7" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume at 1 Second (FEV1)</title>
        <description>Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
        <time_frame>12 weeks</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume at 1 Second (FEV1)</title>
          <description>Centralized spirometry according to internationally accepted standards was used. The model contained treatment, baseline smoking status and baseline inhaled corticosteroid (ICS) use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in region as a random effect. If trough FEV1 was missing at week 12, the latest non-missing pre-dose trough FEV1 (the mean of 45 and 15 min pre-dose measurements) from day 29, 57 or 84) was carried forward. These measurements had to have been taken before the next dose of study medication. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.499" spread="0.0135"/>
                    <measurement group_id="O2" value="1.436" spread="0.0136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose</title>
        <description>Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
        <time_frame>12 weeks</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV(1) Area Under the Curve (AUC) During 30 Minutes to 4 Hours Post Dose</title>
          <description>Centralized spirometry was used according to internationally accepted standards was used. The trapezoidal rule was applied to calculate FEV1 Area Under the Curve (AUC) and then normalized to the length of time. Whether the participants had complete or incomplete FEV1 assessments in respective time ranges, their AUCs were calculated based on the existing FEV1 measurements (i.e., the missing FEV1 measurements were not interpolated). Specifically, for those participants who had a FEV1 assessment at only one time-point, their AUC was approximated by the observed FEV1. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.641" spread="0.0132"/>
                    <measurement group_id="O2" value="1.530" spread="0.0134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks</title>
        <description>Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
        <time_frame>12 weeks</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 During 30 Minutes to 4 Hours Post-dose at 12 Weeks</title>
          <description>Centralized spirometry was used according to internationally accepted standards was used. Peak FEV1 was defined as the maximum FEV1 during the first 4 hours post morning dosing. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilator as covariates and center nested in a region as a random effect. If all FEV1 measurements were missing from 30 minutes onward, the peak FEV1 was not calculated. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.702" spread="0.0137"/>
                    <measurement group_id="O2" value="1.596" spread="0.0138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at Individual Time-points</title>
        <description>Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
        <time_frame>Day 1, Day 29, Day 57 and Days 84/85</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at Individual Time-points</title>
          <description>Centralized spirometry according to internationally accepted standards was used. FEV1 was measured at all post-dose time points up to 4 hours, and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FEV1, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FEV1 measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were not included in the analysis.</description>
          <population>Full Analysis Set</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 30 minutes (min) post dose (n=208,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.544" spread="0.0086"/>
                    <measurement group_id="O2" value="1.467" spread="0.0088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 hour (h) post dose (n=214,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.589" spread="0.0102"/>
                    <measurement group_id="O2" value="1.479" spread="0.0104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 h post dose (n=212,207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.626" spread="0.0114"/>
                    <measurement group_id="O2" value="1.506" spread="0.0117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 h post dose (n=206,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.630" spread="0.0122"/>
                    <measurement group_id="O2" value="1.518" spread="0.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 23 h 15 min post dose (n=201,203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.481" spread="0.0118"/>
                    <measurement group_id="O2" value="1.409" spread="0.0118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 23 h 45 min post dose (n=213,204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.502" spread="0.0109"/>
                    <measurement group_id="O2" value="1.425" spread="0.0112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 45 min pre-dose (n=198,202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.491" spread="0.0150"/>
                    <measurement group_id="O2" value="1.438" spread="0.0150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 15 min pre-dose (n=198,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.524" spread="0.0156"/>
                    <measurement group_id="O2" value="1.470" spread="0.0155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 30 min post dose (n=202,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.617" spread="0.0152"/>
                    <measurement group_id="O2" value="1.508" spread="0.0154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 1 h post dose (n=200,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.648" spread="0.0144"/>
                    <measurement group_id="O2" value="1.524" spread="0.0145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 45 min pre-dose (n=201,202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.482" spread="0.0145"/>
                    <measurement group_id="O2" value="1.418" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 15 min pre-dose (n=199,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.509" spread="0.0148"/>
                    <measurement group_id="O2" value="1.443" spread="0.0149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 30 min post dose (n=200,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.606" spread="0.0144"/>
                    <measurement group_id="O2" value="1.495" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 1 h post dose (n=197,204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.634" spread="0.0149"/>
                    <measurement group_id="O2" value="1.520" spread="0.0148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 45 min pre-dose (n=201,206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.459" spread="0.0127"/>
                    <measurement group_id="O2" value="1.411" spread="0.0126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 15 min pre-dose (n=190,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.476" spread="0.0129"/>
                    <measurement group_id="O2" value="1.439" spread="0.0129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 30 min post dose (n=198,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.604" spread="0.0125"/>
                    <measurement group_id="O2" value="1.514" spread="0.0126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 1 h post dose (n=201,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.638" spread="0.0125"/>
                    <measurement group_id="O2" value="1.514" spread="0.0126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 2 h post dose (n=198,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.665" spread="0.0139"/>
                    <measurement group_id="O2" value="1.542" spread="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 4 h post dose (n=200,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.620" spread="0.0162"/>
                    <measurement group_id="O2" value="1.529" spread="0.0165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 23 h 15 min post dose (n=193,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.474" spread="0.0139"/>
                    <measurement group_id="O2" value="1.426" spread="0.0143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 23 h 45 min post dose (n=197,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.508" spread="0.0147"/>
                    <measurement group_id="O2" value="1.452" spread="0.0148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at Individual Time-points</title>
        <description>FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.</description>
        <time_frame>Day 1, Day 29, Day 57 and Days 84/85</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at Individual Time-points</title>
          <description>FVC was calculated at each time point up to 4 hours post-dose and at 23 hours 15 minutes and 23 hours 45 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of FVC, FEV1 prior to inhaltion of short acting bronchodilators and FEV1 post inhaltion of short acting bronchodilators as covariates and center nested in region as a random effect. FVC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 30 min post dose (n=208,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.214" spread="0.0181"/>
                    <measurement group_id="O2" value="3.135" spread="0.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 h post dose (n=214,209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.295" spread="0.0260"/>
                    <measurement group_id="O2" value="3.182" spread="0.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 2 h post dose (n=212,207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.325" spread="0.0229"/>
                    <measurement group_id="O2" value="3.200" spread="0.0234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 4 h post dose (n=206,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.340" spread="0.0239"/>
                    <measurement group_id="O2" value="3.218" spread="0.0238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 23 h 15 min post dose (n=201,203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.155" spread="0.0267"/>
                    <measurement group_id="O2" value="3.039" spread="0.0268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 23 h 45 min post dose (n=213,204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.201" spread="0.0257"/>
                    <measurement group_id="O2" value="3.095" spread="0.0263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 45 min pre-dose (n=198,202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.146" spread="0.0299"/>
                    <measurement group_id="O2" value="3.043" spread="0.0299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 15 min pre-dose (n=198,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.184" spread="0.0315"/>
                    <measurement group_id="O2" value="3.092" spread="0.0314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 30 min post dose (n=202,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.316" spread="0.0338"/>
                    <measurement group_id="O2" value="3.201" spread="0.0341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, 1 h post dose (n=200,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.362" spread="0.0336"/>
                    <measurement group_id="O2" value="3.197" spread="0.0337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 45 min pre-dose (n=201,202)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.102" spread="0.0302"/>
                    <measurement group_id="O2" value="3.015" spread="0.0303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 15 min pre-dose (n=199,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.156" spread="0.0321"/>
                    <measurement group_id="O2" value="3.086" spread="0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 30 min post dose (n=200,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.282" spread="0.0316"/>
                    <measurement group_id="O2" value="3.190" spread="0.0319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56, 1 h post dose (n=197,204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.327" spread="0.0323"/>
                    <measurement group_id="O2" value="3.219" spread="0.0321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 45 min pre-dose (n=201,206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.052" spread="0.0280"/>
                    <measurement group_id="O2" value="3.016" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 15 min pre-dose (n=190,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.064" spread="0.0256"/>
                    <measurement group_id="O2" value="3.012" spread="0.0254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 30 min post dose (n=198,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.246" spread="0.0262"/>
                    <measurement group_id="O2" value="3.162" spread="0.0264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 1 h post dose (n=201,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.312" spread="0.0291"/>
                    <measurement group_id="O2" value="3.179" spread="0.0294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 2 h post dose (n=198,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.318" spread="0.0261"/>
                    <measurement group_id="O2" value="3.181" spread="0.0261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 4 h post dose (n=200,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.251" spread="0.0292"/>
                    <measurement group_id="O2" value="3.161" spread="0.0297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 23 h 15 min post dose (n=193,188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.123" spread="0.0285"/>
                    <measurement group_id="O2" value="3.050" spread="0.0292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 23 h 45 min post dose (n=197,199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.136" spread="0.0256"/>
                    <measurement group_id="O2" value="3.047" spread="0.0258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inspiratory Capacity (IC) at Individual Time-points</title>
        <description>Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.</description>
        <time_frame>Day 1, Days 84/85</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity (IC) at Individual Time-points</title>
          <description>Inspiratory Capacity (IC) was measured at 20 min pre-dose and at post-dose at 25 minutes, 1 hour 55 minutes, 3 hours 55 minutes and 23 hours 40 minutes, by visit. The model contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline measurement of IC, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. IC measurements within 6 hours of rescue medication use or within 7 days of systemic corticosteroid use were set to missing.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 25 min post dose (n=164,168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.493" spread="0.0234"/>
                    <measurement group_id="O2" value="2.434" spread="0.0231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 1 h 55 min (n=161,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.587" spread="0.0294"/>
                    <measurement group_id="O2" value="2.478" spread="0.0287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 3 h 55 min (n=160,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.557" spread="0.0298"/>
                    <measurement group_id="O2" value="2.475" spread="0.0291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 20 min pre-dose (n=144,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.444" spread="0.0327"/>
                    <measurement group_id="O2" value="2.363" spread="0.0324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 25 min post dose (n=149,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.580" spread="0.0372"/>
                    <measurement group_id="O2" value="2.420" spread="0.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 1 h 55 min post dose (n=146,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.607" spread="0.0388"/>
                    <measurement group_id="O2" value="2.485" spread="0.0384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 3 h 55 min (n=146,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.577" spread="0.0332"/>
                    <measurement group_id="O2" value="2.439" spread="0.0333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 84/85, 23 h 40 min (n=153,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.405" spread="0.0371"/>
                    <measurement group_id="O2" value="2.337" spread="0.0376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Daily Number of Puffs of Rescue Medication</title>
        <description>The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Daily Number of Puffs of Rescue Medication</title>
          <description>The number of puffs of rescue medication taken in the previous 12 hours was recorded in the patient diary in the morning and evening. The total number of puffs of rescue medication per day over the whole active treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.16"/>
                    <measurement group_id="O2" value="-1.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transitional Dyspnea Index (TDI) Focal Score</title>
        <description>Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Transitional Dyspnea Index (TDI) Focal Score</title>
          <description>Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during treatment using the Transitional Dyspnea Index (TDI). Analysis was done via mixed model. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort. BDI domains were rated from 0 (severe) to 4 (unimpaired) and rates summed for baseline focal score ranged from 0 to 12; lower scores mean worse severity. TDI domains were rated from -3 (major deterioration) to 3 (major improvement) and rates summed for transition focal score ranged from -9 to 9; negative scores indicate deterioration. A TDI focal score of 1 is considered a minimal clinically important difference.</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.506" spread="0.2781"/>
                    <measurement group_id="O2" value="2.012" spread="0.2797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Daily Total and Individual Symptom Scores</title>
        <description>The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Daily Total and Individual Symptom Scores</title>
          <description>The symptoms (respiratory, cough, wheeze, sputum color, sputum production, breathlessness, sore throat, nasal discharge or congestion, and fever) for the whole active treatment period was analyzed using a mixed model, which contained treatment, baseline smoking status and baseline ICS use as fixed effects with the baseline symptom score, FEV1 prior to inhalation of short acting bronchodilators and FEV1 post inhalation of short acting bronchodilators as covariates and center nested in region as a random effect. Each symptom was scored as 0, 1, 2 or 3 where the description for each score varied. For each of the symptoms, the range of scores from 0 to 3 represented an increase in symptoms where 0 represented little to no symptom and 3 represented severe or worst symptom. The total symptom score, which is the sum of the individual scores, ranged from 0 (best possible outcome) to 27 (worst possible outcome).</description>
          <population>Only participants from the full analysis set, who had outcome measure data with applicable fixed effects/covariates according to the analysis model, were analyzed.</population>
          <units>Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.13"/>
                    <measurement group_id="O2" value="-1.1" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.03"/>
                    <measurement group_id="O2" value="-0.2" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.03"/>
                    <measurement group_id="O2" value="-0.2" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheeze symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.03"/>
                    <measurement group_id="O2" value="-0.2" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sputum production score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.03"/>
                    <measurement group_id="O2" value="-0.1" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sputum color score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.02"/>
                    <measurement group_id="O2" value="-0.1" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathless symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.03"/>
                    <measurement group_id="O2" value="-0.2" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.01"/>
                    <measurement group_id="O2" value="0.0" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.02"/>
                    <measurement group_id="O2" value="0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever symptom score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.01"/>
                    <measurement group_id="O2" value="0.0" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.</description>
        <time_frame>12 weeks</time_frame>
        <population>Safety Set: The safety set included all patients who received at least one dose of study drug whether or not they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
          </group>
          <group group_id="O2">
            <title>Placebo to NVA237 + Indacaterol</title>
            <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>All study emergent adverse events including Chronic Obstructive Pulmonary Disease exacerbations were monitored from screening through the end of study.</description>
          <population>Safety Set: The safety set included all patients who received at least one dose of study drug whether or not they were randomized.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events (serious and non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NVA237 + Indacaterol</title>
          <description>Participants received Indacaterol 150 ug once daily delivered via single dose dry powder inhaler (SDDPI) plus NVA237 50 ug once daily delivered via SDDPI</description>
        </group>
        <group group_id="E2">
          <title>Placebo to NVA237 + Indacaterol</title>
          <description>Participants received Indacaterol 150 ug once daily delivered via SDDPI plus placebo to NVA237 delivered via SDDPI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

